Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 6];6(6):s48. Available from: https://skin.dermsquared.com/skin/article/view/1803